The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $6.65

Today's change0.00 0.00%
Updated May 4 4:00 PM EDT. Delayed by at least 15 minutes.
 

ARIAD Pharmaceuticals Inc

Nasdaq: ARIA
Last

(U.S.) $6.65

Today's change0.00 0.00%
Updated May 4 4:00 PM EDT. Delayed by at least 15 minutes.

ARIAD Pharmaceuticals Inc closed at (U.S.)$6.65.

Shares have lost 7.89% over the last five days, but have gained 6.40% over the last year to date. This security has underperformed the S&P 500 by 25.03% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $6.65
  • High--
  • Low--
  • Bid / Ask(U.S.) $6.32 / (U.S.) $7.04
  • YTD % change+6.40%
  • Volume0
  • Average volume (10-day)2,364,329
  • Average volume (1-month)3,309,647
  • Average volume (3-month)3,774,107
  • 52-week range(U.S.) $4.37 to (U.S.) $10.07
  • Beta1.72
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.23
Updated May 4 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-194.57%

Although this company's net profit margin is negative, it is above the industry average and implies that ARIAD Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.55%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue37292924
Total other revenue--------
Total revenue37292924
Gross profit36292923
Total cost of revenue0001
Total operating expense89858874
Selling / general / administrative44374934
Research & development45483939
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-53-56-59-50
Interest income (expense), net non-operating-5-5-4-4
Gain (loss) on sale of assets--------
Other--------
Income before tax-58-61-63-52
Income after tax-60-55-63-53
Income tax, total2-600
Net income-60-55-63-53
Total adjustments to net income--------
Net income before extra. items-60-55-63-53
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-60-55-63-53
Inc. avail. to common incl. extra. items-60-55-63-53
Diluted net income-60-55-63-53
Dilution adjustment00----
Diluted weighted average shares189189189188
Diluted EPS excluding extraordinary itemsvalue per share-0.32-0.29-0.33-0.28
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.32-0.29-0.33-0.28